| 产品名称: | NCI-H2122 H2122 |
|---|---|
| 商品货号: | TS211305 |
| Organism: | Homo sapiens, human |
| Tissue: | lung; derived from metastatic site: pleural effusion |
| Cell Type: | lymphoblast |
| Product Format: | frozen |
| Morphology: | it is normal for CRL-5985 to show a mixed morphology of rounded cells and epithelial cells. This cell line produces moderate to large, viable, loose, grape-like clusters that either loosely adhere to the flask or remain in suspension |
| Culture Properties: | adherent |
| Biosafety Level: | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease: | stage 4, adenocarcinoma; non-small cell lung cancer |
| Age: | 46 years |
| Gender: | female |
| Ethnicity: | Caucasian, White |
| Storage Conditions: | liquid nitrogen vapor phase |
| Derivation: | The line was established in January 1989 from pleural effusion metastasis of lung. |
| Clinical Data: | 46 years Caucasian female The patient was a smoker 30 pack year |
| Comments: | A lymphoblastoid line from the same patient is available as ATCC CRL-5967.
|
| Complete Growth Medium: | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing: |
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days |
| Cryopreservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions: | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile: | Amelogenin: X CSF1PO: 10 D13S317: 10 D16S539: 9,12 D5S818: 11,12 D7S820: 8,10 THO1: 7,9.3 TPOX: 9 vWA: 17 |
| Name of Depositor: | AF Gazdar, JD Minna |
| Deposited As: | Homo sapiens |
| Year of Origin: | January, 1989 |
| References: | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. |